Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

907 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.
Passalacqua R, Buzio C, Buti S, Porta C, Labianca R, Pezzuolo D, Camisa R, Sabbatini R, Benecchi L, Messina C, Cengarle R, Vaglio A, Dalla Chiesa M, Tomasello G, Caminiti C. Passalacqua R, et al. Among authors: messina c. Cancer Immunol Immunother. 2010 Apr;59(4):553-61. doi: 10.1007/s00262-009-0773-9. Epub 2009 Sep 25. Cancer Immunol Immunother. 2010. PMID: 19779715 Free PMC article. Clinical Trial.
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.
Iacovelli R, Cartenì G, Sternberg CN, Milella M, Santoni M, Di Lorenzo G, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Ruggeri EM, Berruti A, Cerbone L, Procopio G. Iacovelli R, et al. Among authors: messina c. Eur J Cancer. 2013 Jun;49(9):2134-42. doi: 10.1016/j.ejca.2013.02.032. Epub 2013 Mar 18. Eur J Cancer. 2013. PMID: 23518211
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial.
Caffo O, Ortega C, Nolè F, Gasparro D, Mucciarini C, Aieta M, Zagonel V, Iacovelli R, De Giorgi U, Facchini G, Veccia A, Palesandro E, Verri E, Buti S, Razzini G, Bozza G, Maruzzo M, Ciccarese C, Schepisi G, Rossetti S, Maines F, Kinspergher S, Fratino L, Ermacora P, Nicodemo M, Giordano M, Sartori D, Scapoli D, Sabbatini R, Lo Re G, Morelli F, D'Angelo A, Vittimberga I, Lippe P, Carrozza F, Messina C, Galli L, Valcamonico F, Porta C, Pappagallo G, Aglietta M. Caffo O, et al. Among authors: messina c. Eur J Cancer. 2021 Sep;155:56-63. doi: 10.1016/j.ejca.2021.06.016. Epub 2021 Aug 3. Eur J Cancer. 2021. PMID: 34358777 Clinical Trial.
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.
Iacovelli R, Farcomeni A, Sternberg CN, Cartenì G, Milella M, Santoni M, Cerbone L, Di Lorenzo G, Verzoni E, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Maria Ruggeri E, Berruti A, Procopio G. Iacovelli R, et al. Among authors: messina c. J Urol. 2015 Jun;193(6):1905-10. doi: 10.1016/j.juro.2014.11.092. Epub 2014 Nov 26. J Urol. 2015. PMID: 25433306
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program.
Maines F, De Giorgi U, Procopio G, Facchini G, Fratino L, Sabbatini R, Gasparro D, Basso U, Mosillo C, Campadelli E, Massari F, Sava T, Sirotova S, Messina C, Scagliarini S, Conteduca V, Verzoni E, Rossetti S, Veccia A, Kinspergher S, Caffo O. Maines F, et al. Among authors: messina c. Future Oncol. 2018 Nov;14(26):2691-2699. doi: 10.2217/fon-2018-0113. Epub 2018 Sep 12. Future Oncol. 2018. PMID: 30207488 Clinical Trial.
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study.
Caffo O, De Giorgi U, Fratino L, Alesini D, Zagonel V, Facchini G, Gasparro D, Ortega C, Tucci M, Verderame F, Campadelli E, Lo Re G, Procopio G, Sabbatini R, Donini M, Morelli F, Sartori D, Zucali P, Carrozza F, D'Angelo A, Vicario G, Massari F, Santini D, Sava T, Messina C, Fornarini G, La Torre L, Ricotta R, Aieta M, Mucciarini C, Zustovich F, Macrini S, Burgio SL, Santarossa S, D'Aniello C, Basso U, Tarasconi S, Cortesi E, Buttigliero C, Ruatta F, Veccia A, Conteduca V, Maines F, Galligioni E. Caffo O, et al. Among authors: messina c. Eur Urol. 2015 Jul;68(1):147-53. doi: 10.1016/j.eururo.2014.10.014. Epub 2014 Oct 25. Eur Urol. 2015. PMID: 25457020
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
Conteduca V, Caffo O, Fratino L, Lo Re G, Basso U, D'Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Ermacora P, Messina C, Giordano M, Alesini D, Zagonel V, Veccia A, Lolli C, Maines F, De Giorgi U. Conteduca V, et al. Among authors: messina c. Future Oncol. 2015;11(21):2881-91. doi: 10.2217/fon.15.158. Epub 2015 Oct 5. Future Oncol. 2015. PMID: 26436290
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer.
Veccia A, Caffo O, De Giorgi U, Di Lorenzo G, Ortega C, Scognamiglio F, Aieta M, Facchini G, Mansueto G, Mattioli R, Procopio G, Zagonel V, D'Angelo A, Spizzo G, Bortolus R, Donini M, Lo Re G, Massari F, Vicario G, Zucali PA, Alesini D, Bonetti A, Mucciarini C, Nicodemo M, Berruti A, Fratino L, Lodde M, Messina C, Perin A, Santini D, Sava T, Tucci M, Basso U, Maines F, Burgio LS, Galligioni E. Veccia A, et al. Among authors: messina c. Future Oncol. 2016 Feb;12(4):493-502. doi: 10.2217/fon.15.302. Epub 2016 Jan 18. Future Oncol. 2016. PMID: 26776493
Safety and Clinical Outcomes of Abiraterone Acetate After Docetaxel in Octogenarians With Metastatic Castration-Resistant Prostate Cancer: Results of the Italian Compassionate Use Named Patient Programme.
Maines F, Caffo O, De Giorgi U, Fratino L, Lo Re G, Zagonel V, D'Angelo A, Donini M, Verderame F, Ratta R, Procopio G, Campadelli E, Massari F, Gasparro D, Ermacora P, Messina C, Giordano M, Alesini D, Basso U, Fraccon AP, Vicario G, Conteduca V, Galligioni E. Maines F, et al. Among authors: messina c. Clin Genitourin Cancer. 2016 Feb;14(1):48-55. doi: 10.1016/j.clgc.2015.07.019. Epub 2015 Aug 6. Clin Genitourin Cancer. 2016. PMID: 26382222
907 results